Aims and objectives
INTRODUCTION Digital breast tomosynthesis (DBT),
also known as 3D mammography has been widely accepted and rapidly used in combination with standard full field digital mammography (SFFDM) or 2D mammography since its approval by the US Food and Drug Administration (FDA) in 2011.
It has shown to have better clinical performance for both screening and diagnostic imaging for breast cancer [2].The main reason for the need for 2D mammograms in addition to DBT is better assessment of breast...
Methods and materials
Patient selection Retrospective study was conducted in patients presenting to breast cancer clinic in our institution from April 2016 to October 2016.
Patients complaining of breast lump or breast pain were enrolled.
All the patients with previous breast surgery or on chemotherapy were excluded. Study design and Image interpretation Mammograms were done using Hologic Selenia Dimensions ® in COMBO-HD mode.
The COMBO-HD mode acquires both DBT and SFFDM images in the same compression and...
Results
Out of total 59 lesions in 47 patients,
30 lesions were in right breast and 29 in the left breast. Breast density and lesion density in synthesized views were recorded lesser than the standard views and the difference was statistically significant (p<0.002) [TABLE 1 & 2]. Kappa coefficient was 0.626 and there was 72.6 % agreement between both the sets. The distribution of the breast density patterns in SM images as compared to SFFDM Percentage of patients with ACR a was 13.6% more in SM. In...
Conclusion
The diagnostic performance of the SM vs.
SFFDM is comparable in detection characterisation of lesion,
microcalcification and architectural distortion. Though there was a significant difference in breast density and lesion density where in synthesized views it was lower as compared to SFFDM,
there was no significant difference in the BIRADS classification and ultimately the management. Synthesized view not only offers decreased radiation exposure but also the benefit of improved patient...
References
Hologic,
submission to FDA panel for approval of tomosynthesis.
"FDA." http://www.fda.gov.
September 24,
2010.
http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/ AdvisoryCommittee/RadiologicalDevicesPanel/UCM226757.pdf.
(Accessed December 18,
2016). Skaane P,
Gullien R,
Bjørndal H,
et al.
Digital breast tomosynthesis (DBT): initial experience in a clinical setting.
Acta Radiol 2012;53(5):524–529.
Friedewald SM,
Rafferty EA,
Rose SL,
et al.
Breast...
